Literature DB >> 19308030

Inflammatory activation and left ventricular mass in essential hypertension.

Esther Roselló-Lletí1, Miguel Rivera, Luís Martínez-Dolz, Jose R González Juanatey, Raquel Cortés, Alejandro Jordán, Pedro Morillas, Catheline Lauwers, Jose R Calabuig, Isabel Antorrena, Beatriz de Rivas, Manuel Portolés, Vicente Bertomeu.   

Abstract

BACKGROUND: Inflammation is an independent risk factor for high blood pressure, and as a consequence inflammatory cytokines could be related with left ventricular hypertrophy (LVH). We sought to assess the association and predictive role of different cytokine levels with LVH in a group of patients with essential hypertension (HT).
METHODS: We studied 251 asymptomatic hypertensive patients (142 with LVH and 109 without LVH), referred from 11 hospitals. A routine physical examination, laboratory analyses, and echo-Doppler study were performed. Plasma soluble tumor necrosis factor (TNF) receptors (sTNF-R1 and sTNF-R2), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1ra) were centrally determined.
RESULTS: Hypertensive patients with LVH had higher inflammatory cytokine levels than the group without hypertrophy (P < 0.001). Multivariate linear regression reported that sTNF-R1 (P < 0.01) was an independent predictor of left ventricular mass index (LVMI). All cytokines had significant area under the curves for detection of LVH, but sTNF-R1 has the highest area, 0.71 +/- 0.03 (P < 0.001). Finally, prevalence of LVH was increased in the group of patients with higher cytokine levels, and logistic regression analysis showed that sTNF-R1 (odds ratio = 2.59, 95% CI of 1.14-5.87) was an independent predictor of LVH.
CONCLUSIONS: Cytokine levels were significantly correlated with LVMI in hypertensive patients. The sTNF-R1 was an independent predictor of LVMI. Plasma sTNF-R1 concentrations could be a predictive factor of LVH in patients with essential HT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19308030     DOI: 10.1038/ajh.2008.369

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  10 in total

Review 1.  Integrating Measures of Myocardial Fibrosis in the Transition from Hypertensive Heart Disease to Heart Failure.

Authors:  R Brandon Stacey; W Gregory Hundley
Journal:  Curr Hypertens Rep       Date:  2021-04-21       Impact factor: 5.369

2.  Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study.

Authors:  Michael O Harhay; Russell P Tracy; Emilia Bagiella; R Graham Barr; Diane Pinder; W Gregory Hundley; David A Bluemke; Richard A Kronmal; Joao A C Lima; Steven M Kawut
Journal:  Int J Cardiol       Date:  2013-08-09       Impact factor: 4.164

3.  Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.

Authors:  Jiwon Kim; Spencer Krichevsky; Lola Xie; Maria Chiara Palumbo; Sara Rodriguez-Diego; Brian Yum; Lillian Brouwer; Richard T Silver; Andrew I Schafer; Ellen K Ritchie; Maria Mia Yabut; Claudia Sosner; Evelyn M Horn; Richard B Devereux; Joseph M Scandura; Jonathan W Weinsaft
Journal:  J Am Soc Echocardiogr       Date:  2019-10-03       Impact factor: 5.251

4.  Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life.

Authors:  Aaron J Cohen; Kanako Teramoto; Brian Claggett; Leo Buckley; Scott Solomon; Christie Ballantyne; Elizabeth Selvin; Amil M Shah
Journal:  J Card Fail       Date:  2021-07-25       Impact factor: 5.712

5.  Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.

Authors:  Esther Roselló-Lletí; Jose R Calabuig; Pedro Morillas; Raquel Cortés; Luis Martínez-Dolz; Luis Almenar; Jose R González-Juanatey; Catheline Lauwers; Antonio Salvador; Manuel Portolés; Vicente Bertomeu; Miguel Rivera
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

6.  Inflammation and echocardiographic parameters of ventricular hypertrophy in a cohort with preserved cardiac function.

Authors:  D Medenwald; S Dietz; D Tiller; A Kluttig; Kh Greiser; H Loppnow; J Thiery; S Nuding; M Russ; A Fahrig; J Haerting; K Werdan
Journal:  Open Heart       Date:  2014-02-08

7.  The Protective Effect of Aspirin against Myocardial Hypertrophy in Rats.

Authors:  Xiaolong Wu; Minghui Wei; Haifeng Zhang; Xiaomei Fan; Xiaochen Ma; Jiaming Liu; Mingming Xue
Journal:  Biomed Res Int       Date:  2021-04-20       Impact factor: 3.411

8.  Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus.

Authors:  Christos Papageorgiou; Flora Zagouri; Konstantinos Tampakis; Rebecca Georgakopoulou; Efstathios Manios; Pavlos Kafouris; Georgios Benetos; Iosif Koutagiar; Constantinos Anagnostopoulos; Meletios A Dimopoulos; Konstantinos Toutouzas
Journal:  Front Cardiovasc Med       Date:  2021-02-23

Review 9.  Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups.

Authors:  Simon W Rabkin
Journal:  EXCLI J       Date:  2022-02-22       Impact factor: 4.068

10.  MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study.

Authors:  Núria Carpena; Esther Roselló-Lletí; Jose R Calabuig; Estefanía Tarazón; Jose R González-Juanatey; Luis Martínez-Dolz; Antonio Salvador; Lilian Grigorian; Plácido Orosa; Manuel Portolés; Miguel Rivera
Journal:  ISRN Cardiol       Date:  2012-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.